Findings from Razanne Oueini and Colleagues Provides New Insights into Proinsulin (Changes in persistence to basal insulin following the Medicare out-of-pocket cost cap): Peptide Proteins – Proinsulin

2026 JUL 06 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- A new study on Peptide Proteins - Proinsulin is now available. According to news reporting originating in Alexandria, Virginia, by NewsRx journalists, research stated, “To evaluate changes in persistence to basal insulin following the implementation of the $35 monthly out-of-pocket cost cap for insulin for Medicare beneficiaries. We completed a retrospective cohort analysis of a nationally representative Medicare Advantage sample from 2022 to 2023.”

The news reporters obtained a quote from the research, “We compared precap rates of persistence to basal insulin in 2022 with postcap rates in 2023 using Persistence to Basal Insulin, a health plan performance measure used in Medicare Part D quality programs, among the study population and multiple subgroups. A statistically significant increase (+1.3 percentage points; P< .001) was seen in overall patient persistence to basal insulin in the first year of the implementation of the insulin cost cap. Subgroup analyses showed greater increases in persistence in several subpopulations, including patients aged 45 to 54 and 65 to 74 years, male patients, non-Hispanic Black patients, and patients residing in certain census divisions, especially those with a high prevalence of type 2 diabetes. In addition to providing financial relief to Medicare patients, the implementation of the insulin cost cap was associated with an improvement in patients’ treatment persistence to basal insulin therapy, a measure associated with positive health and economic outcomes.”

According to the news reporters, the research concluded: “These results lend useful insight into future policy evaluations and proposals that seek to improve treatment access and address disparities in appropriate medication use.”

This research has been peer-reviewed.

For more information on this research see: Changes in persistence to basal insulin following the Medicare out-of-pocket cost cap. The American Journal of Managed Care, 2026;32(6). The American Journal of Managed Care can be contacted at: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

Our news correspondents report that additional information may be obtained by contacting Razanne Oueini, Pharmacy Quality Alliance, 5911 Kingstowne Village Pkwy, Ste 130, Alexandria, VA 22314. Additional authors for this research include Ben Shirley, Christie Teigland, Melissa Castora-Binkley, Scott Bilder, Kiran Sunkari and Lynn Pezzullo.

The publisher of the The American Journal of Managed Care can be contacted at: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)